From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle

April 1, 2018
LCGC Europe
Volume 31, Issue 4
Page Number: 229

The Chromatographic Society and Joint Pharmaceutical Analysis Group have announced a one‑day meeting titled From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle. The meeting will be held at Burlington House, London, UK, on Thursday 10 May 2018.

The Chromatographic Society and Joint Pharmaceutical Analysis Group have announced a one‑day meeting titled From Cradle to Grave: The Chromatographic (Analytical) Method Life Cycle. The meeting will be held at Burlington House, London, UK, on Thursday 10 May 2018.

The meeting aims to provide clear insights into successful strategies in critical areas including method development, validation, transfer, and life cycle management in the pharmaceutical industry, and the latest regulatory expectations, specifically quality-by-design (QbD) and permitted chromatographic method changes according to main pharmacopoeias.

The presentations will be delivered by highly regarded international speakers from industry, regulators, and the chromatography industry. The calibre of the speakers, combined with a fully integrated exhibition and vendor presentation programme, will deliver a highly interesting and well attended event, according to the organizers. The meeting will provide attendees with a unique means of sharing real experiences with other professionals and will provide excellent networking opportunities. The meeting has been separated into four separate sessions spread across the day.

Session 1:

  • Melissa Hanna-Brown (Pfizer, Sandwich, UK)-State-of-the-art Method Development Concepts and Tools as Part of the Analytical Life Cycle

  • Elena Razzano (MHRA, London, UK)-QbD: Update on Current QbD        Regulatory Expectations. Including the application of analytical QbD,             ICH Q12 life cycle management, and filing expectations

Session 2:

  • Sophie Bailes (AstraZeneca R&D, Macclesfield, UK)-How QbD in the Pharmaceutical Industry has Facilitated New Ways of Developing Robust LC Methods Under Challenging Timelines

Session 3:

  • Claudio Brunelli (Pfizer, Sandwich, UK)-The Current Status and Latest Developments in SFC. Addressing the question “Is modern SFC ready for the QC laboratory?”

  • Vendor sponsored short talks

Session 4:

  • Stuart Williams (Novartis Pharma, Grimsby, UK)-The Complex Topic of Recent Regional Health Authority Requirements

  • Katrin Liebelt (Novartis Pharma AG, Basel, Switzerland)-The Latest Requirements, Concepts, and Approaches for Analytical Validation and   Transfer Strategies

There will also be a poster presentation and interested presenters should submit an abstract to the organizers by 20 April 2018.

ChromSoc student bursaries are available for this event. For further details, please visit: www.chromsoc.com/academic-support.aspx

Registration and further information on the meeting is available at: www.jpag.org/101 and www.chromsoc.com/ChromsocEvents.aspx

For further information on the submission or abstracts, sponsorship, or payment details, e-mail: adrian.clarke@novartis.com